Skip to main content
GENINUS Inc. logo

GENINUS Inc. — Investor Relations & Filings

Ticker · 389030 ISIN · KR7389030008 KO Professional, scientific and technical activities
Open in API
Filings indexed 153 across all filing types
Latest filing 2026-05-22 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 389030

About GENINUS Inc.

https://www.kr-geninus.com/

GENINUS Inc. is a biotechnology company specializing in genomic and multi-omics analysis for precision medicine. The company provides comprehensive solutions for drug development, diagnostics, and clinical research, with a focus on single-cell analysis, cancer genome companion diagnostics, and AI-driven biomarker discovery. Its proprietary platforms include IntelliMed™ for clinical genomics, MEDINSIGHT™ for AI-powered digital pathology, and SPACEINSIGHT™, a cloud-based platform for spatial multi-omics data analysis. By integrating advanced analytics with artificial intelligence, GENINUS delivers genetic insights to support personalized treatment strategies, disease prevention, and the development of novel therapeutics.

Recent filings

Filing Released Lang Actions
전환청구권행사
Share Issue/Capital Change Classification · 80% confidence The document is a regulatory announcement detailing the exercise of conversion rights on a series of convertible bonds, specifying the number of shares to be issued upon conversion and the remaining bond balances. This constitutes a change in the company’s capital (new share issuance). Therefore, it falls under “Share Issue/Capital Change” (SHA).
2026-05-22 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제9기) 2026년 01월 01일~2026년 03월 31일,” which translates to a quarterly report for the first quarter of fiscal year 2026. It contains detailed company overview, financial data, business description, and other substantive content typical of an Interim/Quarterly Report. It is not merely an announcement and includes full financial disclosures for the quarter. Therefore, it should be classified as an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
주요사항보고서(제3자의전환사채매수선택권행사)
Share Issue/Capital Change Classification · 85% confidence The document is a Majors Event Report (“주요사항보고서”) filed under Korean regulation, detailing the exercise of a third party’s purchase option on convertible bonds and the resulting share issuance and capital structure change. It is neither an AGM materials nor a full financial report, but specifically an announcement of convertible bond exercise leading to issuance of new shares. Under the schema, this falls under Share Issue/Capital Change (Code: SHA).
2026-05-12 Korean
주요사항보고서(전환사채매수선택권행사자지정)
Regulatory Filings
2026-05-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 92% confidence The document is an “임원ㆍ주요주주 특정증권등 소유상황보고서” filed with the Korea Securities & Futures Commission and Korea Exchange detailing shareholding changes by a company executive (Lee Sanghyuk). It lists pre- and post-transaction share counts, dates, and insider transaction details. This fits exactly the definition of a Director’s Dealing report.
2026-04-27 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 90% confidence The document is a Korean ‘주식등의 대량보유상황보고서(약식)’ which is a large shareholding report under the Capital Markets Act. It details the number of shares held, changes in holdings, and the reasons for acquisition by KB Investment Co., Ltd. This matches the definition of a Major Shareholding Notification (crossing ownership thresholds), code MRQ.
2026-04-01 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.